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The occurrence of additional cytogenetic abnormalities (ACAs) is common in Philadelphia chromosomee
positive acute lymphoblastic leukemia (Phþ ALL) but is of unknown signiﬁcance in the tyrosine kinase in-
hibitor (TKI) era. We retrospectively analyzed data from a consecutive case series of adults with Phþ ALL who
had undergone allogeneic hematopoietic cell transplantation (alloHCT) at City of Hope between 2003 and
2014. Among 130 adults with Phþ ALL who had TKI therapy before alloHCT, 78 patients had available data on
conventional cytogenetics at diagnosis and were eligible for outcomes analysis. ACAs were observed in 41
patients (53%). There were no statistically signiﬁcant differences in median age, median initial WBC count,
post-HCT TKI maintenance, or disease status at the time of transplant between the Ph-only and ACA cohorts;
however, the Ph-only cohort had a higher rate of minimal residual disease positivity at the time of HCT.
Three-year leukemia-free survival (79.8% versus 39.5%, P ¼ .01) and 3-year overall survival (83% versus 45.6%,
P ¼ .02) were superior in the Ph-only cohort compared with the ACA cohort, respectively. Monosomy 7 was
the most common additional aberration observed in our ACA cohort (n ¼ 12). Thus, when TKI therapy and
alloHCT are used as part of adult Phþ ALL therapy, the presence of ACAs appears to have a signiﬁcant
deleterious effect on outcomes post-HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION with Phþ ALL who had received TKI therapy before consol-
Philadelphia chromosome (Ph) is the most common cy-
togenetic abnormality in adults with acute lymphoblastic
leukemia (ALL) [1,2]. The presence of Ph has long been
considered an adverse prognostic feature and was associated
with dismal outcomes in the preetyrosine kinase inhibitor
(TKI) era. For patients with Phþ ALL treated with chemo-
therapy alone, complete remission (CR) rates were low, and
leukemia relapse was the norm in the absence of allogeneic
hematopoietic stem cell transplantation (alloHCT) [3-6].
Therefore, alloHCT was routinely recommended for eligible
patients with available donors. However, the introduction of
TKIs has drastically improved the outcome of Phþ ALL, and,
currently, remission is achieved in most cases [7,8]. None-
theless, alloHCT continues to be the preferred consolidation
therapy in adults with Phþ ALL because of a lack of long-term
data on patients treated with combination chemotherapy
and TKIs without alloHCT.
Although additional cytogenetic abnormalities (ACAs) at
diagnosis are detected in approximately two thirds of cases
with Phþ ALL [5,9-11], its prognostic signiﬁcance in patients
treated with TKI and alloHCT remains unclear. In this study,
we investigated the prognostic implications of ACAs in adultsedgments on page 1329.
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METHODS
We reviewed all cases of adult Phþ ALL who had undergone alloHCT at
City of Hope Medical Center between January 2003 and April 2014. Only
patients with available conventional cytogenetic documentation of Ph with
an adequate number of analyzed metaphases (20) were included in the
outcomes analysis. We excluded patients younger than 18 years of age and
patients who did not receive pretransplant TKI-based therapy.
Statistical Analysis
Demographic, disease, and treatment characteristics were summarized
using descriptive statistics. The Wilcoxon rank sum test and chi-square test
were used to determine differences in demographic and disease charac-
teristics of interest. Survival estimates were calculated using the Kaplan-
Meier product-limit method [12], and conﬁdence intervals (CIs) were
calculated using the logit transformation and the Greenwood variance es-
timate [13]. Differences between Kaplan-Meier curves were determined
using the log-rank test. Overall survival (OS) was deﬁned as time from date
of transplant to death from any cause. Leukemia-free survival (LFS) was
measured as time from date of transplant to relapse or death from any cause,
whichever occurred ﬁrst. Patients who were alive at the time of analysis
were censored at the last contact date.
Prognostic variables analyzed included patient age at transplant, initial
WBC count, disease status at transplant (ﬁrst CR [CR1] versus beyond CR1),
and cytogenetic risk (isolated versus ACA and isolated versus ACA with 7
versus ACAwithout7). All analyses were performed using SAS version 09.3
(SAS Institute, Cary, NC). Data were locked for analysis August 5, 2014.
RESULTS
We identiﬁed 134 consecutive adults with Phþ ALL who
had undergone alloHCT during the selected time period. Five
cases were excluded because of the lack of pretransplant TKI
therapy. Fifty-one cases with Ph positivity demonstrated
only by PCR and/or ﬂuorescein in situ hybridization for
Table 1
Patient, Disease, and Treatment Characteristics
Variables No t(9;22) Cytogenetics* (n ¼ 51) Isolated Phþ Cytogenetics (n ¼ 37) Phþ Plus ACAs (n ¼ 41)
Age, yr, median (range) 44.3 (18.9-68.5) 49 (19.8-68.4) 38.6 (21.4-61.0)
Gender
Female 22 (43) 17 (46) 13 (32)
Male 29 (57) 20 (54) 28 (68)
WBC count, median (range) 18.2 (1.2-425) 37.1 (1.1-440.0) 22.6 (1.2-426.0)
Disease status
CR1 37 (73) 31 (84) 34 (83)
CR2 or beyond 10 (20) 3 (8) 4 (10)
Active disease at HCT 4 (8) 3 (8) 3 (7)
Cytogenetic remissiony 40/41 (98) 26/29 (90) 29/33 (88)
MRD status pre-HCT
MRD positive 14 (27) 17 (46) 9 (22)
MRD negative 28 (55) 13 (35) 27 (66)
Unknown 9 (18) 7 (19) 5 (12)
Time from diagnosis to transplant, days,
median (range)
210 (75-1748) 135 (71-434) 177 (68-1162)
Pre-HCT TKI
Imatinib 35 (67) 23 (62) 29 (71)
Dasatinib 11 (23) 11 (30) 7 (17)
Imatinib/dasatinib 5 (10) 3 (8) 5 (12)
Post-HCT TKI maintenance
Yes 18 (35) 19 (51) 21 (51)
No 30 (59) 16 (43) 17 (41)
Not applicablez 3 (6) 2 (5) 3 (7)
Donor type
Sibling 29 (57) 16 (43) 19 (46)
Unrelated 22 (43) 21 (57) 22 (54)
Stem cell source
Bone marrow 3 (6) 2 (5) 6 (15)
Cord blood/double cord 4 (8) 0 (0) 6 (15)
Peripheral blood 44 (86) 35 (95) 29 (71)
Conditioning regimen intensity
RIC/NMA 14 (27) 11 (30) 9 (22)
MAC 37 (73) 26 (70) 32 (78)
Conditioning regimens
FTBI/etoposoide 29 (57) 25 (68) 27 (66)
Fludarabine/melphalan 15 (29) 10 (27) 6 (15)
Cytoxan/ﬂudarabine/TBI 7 (14) 0 (0) 6 (15)
Others 0 (0) 2 (5) 2 (5)
Cytogenetic abnormalities
Phþ by FISH or PCR only 51 (100) 0
Phþ by conventional cytogenetics 0 37 (100) 41 (100)
7 NA 0 12
8, i(8) or þ8 NA 0 11
9p del, 9, der(9), add(9p) or þ9 NA 0 11
der(22) NA 0 9
Monosomy, excluding 7 NA 0 8
Hyperdiploidy NA 0 6
MRD indicates minimal residual disease; RIC, reduced-intensity conditioning; NMA, nonmyeloablative; MAC, myeloablative conditioning; FTBI, fractionated
total body irradiation; TBI, total body irradiation; FISH, ﬂuorescein in situ hybridization; NA, not applicable.
Values are number of cases with percents in parentheses, unless otherwise noted.
* By conventional cytogenetics.
y Patients in CR1 or CR2 with available cytogenetics (denominator) who were also in cytogenetic remission (numerator).
z Death within 60 days of HCT.
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ventional cytogenetics (n ¼ 28), no growth/insufﬁcient
growth (n ¼ 12), or karyotyping that did not show
t(9;22)(q34.1;q11.2) (n ¼ 11). Patient and disease character-
istics are shown in Table 1.
Among the 78 cases who met the eligibility criteria, 41
(53%) had ACAs and 37 had isolated t(9;22). There were 4
cases of 3-way complex BCR-ABL1 translocations (variant
translocations with 1 or more chromosomes involved in
addition to 9 and 22) involving chromosomes 6, 7, 10, 14, and
19, of which 3 cases were in the isolated Phþ subgroup and 1
casewas in the ACA subgroup. Themedian agewas 41.4 years
(range, 19.8 to 68.4). Forty-nine patients (63%) were male.
Donors were matched siblings in 35 patients (45%). The
source of stem cells was peripheral blood in 65 patients(83%). The conditioning regimen was myeloablative in 59
patients (76%). Tacrolimus/sirolimus-based graft-versus-host
disease prophylaxis was the most commonly used condi-
tioning regimen, in 59 patients (76%). Patient disease and
transplant characteristics are shown in Table 1.
Monosomy 7 (7) was the most commonly observed ACA
(29%, n ¼ 12) and was the only ACA in 8 cases. The second
most common abnormality was derivative chromosome 22
(n ¼ 9). There were 6 cases of hyperdiploidy (>50 chromo-
somes) in the ACA cohort. The most common trisomies were
6, 8, and 21, seen in 5, 8, and 5 cases, respectively. Most tri-
somies were part of other ACAs. Excluding cases with 7, 8
cases met the deﬁnition of monosomal karyotype (2 auto-
somal monosomies or 1 monosomy combined with struc-
tural aberration). There was 1 case of concurrent occurrence
Figure 1. Survival outcomes stratiﬁed by presence/absence of ACAs. (A) OS and (B) LFS plotted by Kaplan-Meier method. Solid lines represent patients with isolated
Phþ (n ¼ 37), and dashed lines represent patients with Phþ and ACAs (n ¼ 41).
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genetic abnormalities are summarized in Table 1.
There was no difference in median age (P ¼ .08), median
initial WBC (P ¼ .99), disease status at the time of transplant
(P ¼ .58), or post-HCT TKI maintenance therapy (P ¼ .93)
between the isolated Ph and ACA cohorts. However, more
patients with Ph alone had minimal residual disease posi-
tivity (based on BCR/ABL by PCR) before HCT compared with
patients with ACAs (P¼ .0088), as seen in Table 1. Themedian
follow-up for surviving patients from the time of transplant
was 43 months (range, 4.1 to 133) and 47 months (range, 3.2
to 123) for isolated t(9;22) and ACA cohorts, respectively.
Five patients (14%) relapsed in the isolated t(9;22) group and
8 (20%) relapsed in the ACA group. One-year nonrelapse
mortality for thewhole cohort was 20%. The 3-year OS rate of
45.6% (95% CI, 28.2 to 61.5) in the ACA groupwas signiﬁcantly
worse than the 83% (95% CI, 65.9 to 92.0) seen in the isolated
Ph group (P¼ .02). Likewise, the 3-year LFS rate of 39.5% (95%
CI, 23.3 to 55.3) for ACA was signiﬁcantly worse than the
79.8% (95% CI, 62.2 to 89.9) in the isolated Phþ group
(P ¼ .01) (Figure 1). No multivariate analysis was performed
given the small study size and the fact that no signiﬁcant
differences in OS or LFS were seen in univariate analysis
other than the presence of ACAs. The 3-year OS and LFS rates
for the 51 Phþ patients excluded from the analysis were
53.9% and 38.6%, respectively.
Because monosomy 7 was the most common ACA, we
examined its impact on HCT outcomes by splitting the Phþ
cohort into 3 subgroups: isolated Ph, Phþ with 7, and Phþ
with other ACAs. Both 3-year OS and LFS rates were inferiorFigure 2. Survival outcomes stratiﬁed by presence/absence of monosomy 7 and othe
represent patients with isolated Phþ (n ¼ 37), solid gray lines represent patients with
and nonmonosomy 7 ACAs (n ¼ 29).in patients with Phþ and other ACA (non-7) compared with
isolated Phþ and Phþ with 7 cohorts (Figure 2). Three-
year OS rates for Phþ (other ACAs) were 39.7% (95% CI,
20.3 to 58.6) versus 83.0% (95% CI, 65.9 to 92.0) for Phþ
(alone) versus 59.7% (95% CI, 24.1 to 82.9) for Phþ (with 7)
(P ¼ .01). Three-year LFS rates were 30.2% (95% CI, 13.3 to
49.0) for Phþ (other ACAs) versus 79.8% (95% CI, 62.2 to
89.9) for Phþ (alone) versus 60.6% (95% CI, 25.8 to 83.1) Phþ
(with 7) (P ¼ .001).
DISCUSSION
Our study is unique in that it examines the impact of ACAs
in Phþ patients treated with TKIs and consolidated with
alloHCT. Therefore, it is relevant to contemporary manage-
ment of Phþ ALL compared with previous reports examining
this issue [5,9].
ACAs occur frequently in Phþ ALL and have been reported
in over 60% of cases [5,9-11]. Additional aberrations
involving chromosomes 8, 7, 9, 21, and 22 were most
commonly reported [9,10]. In the pre-TKI era, 2 studies
investigated the prognostic signiﬁcance of ACAs in Phþ ALL.
The ﬁrst study included 249 children with Phþ ALL from 10
large pediatric groups diagnosed between 1986 and 1996.
Patients were treated with different regimens, and only 67
patients (27%) underwent alloHCT as part of their ALL
treatment. Event-free survival and OS were lower in patients
with ACAs and loss of chromosomes 7, 7p, and/or 9p, but the
inferior outcome was not signiﬁcant when adjusted to other
prognostic factors [5]. The second analysis included 111
adults with Phþ ALL who were treated in 1 of 7 differentr ACAs. (A) OS and (B) LFS plotted by Kaplan-Meier method. Solid black lines
Phþ and monosomy 7 (n ¼ 12), and dashed lines represent patients with Phþ
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and 2000. Only 24 patients (22%) underwent alloHCT.
Monosomy 7 was associated with a lower CR rate, and
complex cytogenetics (3 abnormalities) was associated
with higher CR rate. The presence of þder(22)t(9;22) was
associated with higher risk of relapse [9]. However, these
previous 2 studies included patients who did not receive TKIs
as part of ALL therapy, and alloHCT was only used in
approximately one fourth of cases.
Our analysis shows inferior LFS and OS in patients with
Phþ ALL with ACAs compared with those with isolated
t(9;22) despite a higher rate of pre-HCT minimal residual
disease positivity in the latter group. Monosomy 7 was the
most common additional abnormality in our cohort and
usually occurred as an isolated extra ﬁnding. The inferior
outcome of the ACA cohort was more pronounced in patients
without monosomy 7 compared with those with monosomy
7. The basis for the worse LFS in the ACA group without
monosomy 7 remains unclear and may be related to the
speciﬁc nature of the more prevalent abnormalities in this
group. The small number of patients makes it difﬁcult to
draw ﬁrm conclusions regarding this observation.
In conclusion, the presence of ACAs, especially in patients
without monosomy 7, appears to adversely impact the post-
transplant outcomes in Phþ ALL when TKI and alloHCT are
used as part of the treatment program. Because of their poor
outcomes, these patients are probably best served if treated
in the context of a clinical trial.We believe these data support
further investigation in an unbiased prospective data set,
which might identify a higher risk group of Phþ ALL patients
who could beneﬁt from additional treatment such as post-
transplant maintenance TKI therapy to reduce relapse risk.
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